A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment Who Are Receiving Dabigatran Etexilate (75 mg twice daily)

Jack Martin,Habib Esmaeili, Raymond C. Manuel,Michaela Petrini,Sabrina Wiebe,Hugo Maas

FASEB JOURNAL（2017）

引用 1|浏览6

暂无评分

摘要

IntroductionDabigatran etexilate (DE) is a direct oral thrombin inhibitor. Dabigatran excretion is 80% renal, and exposure increases with the severity of renal failure. The FDA approved DE 75 mg BI...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要